1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,040 | 9,300 | 16:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | enVVeno Medical receives U.S. patent for venous valve system | 2 | Investing.com | ||
| Di | enVVeno Medical Corporation: enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial | 627 | ACCESS Newswire | New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar... ► Artikel lesen | |
| 22.06. | enVVeno Medical Corporation: enVVeno Medical to Present in the Webull Corporate Connect Webinar Series | 251 | ACCESS Newswire | - Live webcast on Wednesday, June 24th at 2:00 PM ET- Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company... ► Artikel lesen | |
| 02.06. | enVVeno Medical Corporation: enVVeno Medical to Participate in the Virtual Investor Closing Bell Series | 233 | ACCESS Newswire | Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation... ► Artikel lesen | |
| 12.05. | enVVeno Medical Corporation: enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment | 425 | ACCESS Newswire | First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous ValveIDE approval positions enVVeno to advance what could become the first effective treatment option for the... ► Artikel lesen | |
| 07.05. | enVVeno Medical GAAP EPS of -$5.89 | 3 | Seeking Alpha | ||
| 07.05. | enVVeno Medical Corporation: enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System | 627 | ACCESS Newswire | Company ended the first quarter with approximately $25 million in cash and investmentsCapital on hand should fund operations through multiple key milestones into Q3 2027Company recently received FDA... ► Artikel lesen | |
| 06.05. | enVVeno Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| ENVVENO MEDICAL Aktie jetzt für 0€ handeln | |||||
| 29.04. | enVVeno receives FDA approval for venous valve pivotal trial | 2 | Investing.com | ||
| 29.04. | enVVeno Medical Corporation: enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve | 923 | ACCESS Newswire | First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal TrialClinical site activation and patient enrollment expected to commence later this yearLarge unmet clinical need for approximately... ► Artikel lesen | |
| 29.04. | enVVeno Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | enVVeno Medical GAAP EPS of -$33.06 | 2 | Seeking Alpha | ||
| 27.03. | enVVeno Medical Corporation: enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe System | 817 | ACCESS Newswire | Company accelerated development of the enVVe System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiationStrong financial position expected to provide an operating... ► Artikel lesen | |
| 26.03. | enVVeno Medical Corp - 10-K, Annual Report | 2 | SEC Filings | ||
| 04.02. | enVVeno Medical regains Nasdaq compliance, reports $28 million cash | 3 | Investing.com | ||
| 04.02. | enVVeno Medical Corporation: enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement | 420 | ACCESS Newswire | Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closedReports Cash and Investments of approximately $28 million as of the Year Ended December 31... ► Artikel lesen | |
| 04.02. | enVVeno Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 20.01. | enVVeno Medical Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 20.01. | XFRA 5HJ0: AUSSETZUNG/SUSPENSION | 334 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILENVVENO MED CORP.NEW... ► Artikel lesen | |
| 20.01. | XFRA NEW INSTRUMENTS AVAILABLE ON 20.01.2026 | 793 | Xetra Newsboard | The following instruments on XETRA do have their first trading 20.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 20.01.2026
Aktien
1 DK0010230630 Grønlandsbanken A/S
2... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS MEDICAL CARE | 41,930 | +0,22 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 34,590 | +0,61 % | PRESSESPIEGEL/Unternehmen: PORSCHE, COMMERZBANK, RHEINMETALL, KNORR-BREMSE, UBER, CONDOR, SIEMENS HEALTHINEERS | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
PORSCHE - Im Zuge seines Sanierungskurses baut der Sportwagenhersteller... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 30,600 | +4,51 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Carl Zeiss Meditec mit einem Kursziel von 26,10 Euro auf "Market-Perform" belassen. Dies schrieb Analystin Susannah Ludwig am... ► Artikel lesen | |
| ECKERT & ZIEGLER | 14,830 | -2,75 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| INTUITIVE SURGICAL | 356,70 | +0,11 % | Intuitive Surgical-Aktie: Dreht die Aktie wieder nach oben? | Die Aktie von Intuitive Surgical zeigt nach den deutlichen Kursverlusten der vergangenen Monate wieder erste Erholungstendenzen. Neben starken Fundamentaldaten sorgen auch positive Analysteneinschätzungen... ► Artikel lesen | |
| GERRESHEIMER | 28,480 | -2,06 % | Gerresheimer-Aktie: Worauf Anleger jetzt achten sollten? | Die Gerresheimer-Aktie befindet sich derzeit in einer beeindruckenden Erholungsphase und notiert am Montag bei rund 30 €. Damit hat sich das Papier vom Tief bei knapp 17 € deutlich entfernt. Nach dieser... ► Artikel lesen | |
| MEDTRONIC | 73,40 | -0,05 % | Medtronic gains on reimbursement hopes for blood pressure therapy | ||
| THERMO FISHER | 459,10 | -0,54 % | Persistence Market Research Pvt. Ltd.: Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG | LONDON, July 8, 2026 /PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient... ► Artikel lesen | |
| TELADOC HEALTH | 8,060 | -0,91 % | Teladoc (TDOC) Rises Higher Than Market: Key Facts | ||
| STRATEC | 19,000 | +1,82 % | EQS-PVR: STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: STRATEC SE
STRATEC SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| RHOEN-KLINIKUM | 13,500 | -2,88 % | Hochkomplexer Aorteneingriff am RHÖN-Klinikum Frankfurt (Oder) | Frankfurt (Oder) (ots) - - Offene Notfalloperation bei rupturiertem Aneurysma durchgeführt- Eingriff zählt zu den anspruchsvollsten Verfahren der GefäßchirurgieDie Klinik für Gefäßchirurgie am RHÖN-Klinikum... ► Artikel lesen | |
| EUROFINS SCIENTIFIC | 68,52 | -0,35 % | Eurofins Scientific SE: Eurofins Scientific: Director/PDMR Shareholding | Eurofins (Paris:ERF):
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities ("PDMR"). The notification of Dealing Form... ► Artikel lesen | |
| FRESENIUS | 42,570 | +0,83 % | DAX nach Rekord tiefer: Börsen-Beben in Südkorea - Bayer, Rheinmetall, Fresenius und Kion ... | Beim deutschen Leitindex zeichnet sich am Dienstag ein schwächerer Start in den Handelstag ab. Schlechte Vorgaben aus Asien belasten den DAX. Während der Nikkei zur Stunde rund zwei Prozent verliert... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 71,44 | +0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| LIFESTANCE HEALTH GROUP | 10,705 | 0,00 % | LifeStance Health Group, Inc. - 8-K, Current Report |
Das Unternehmen ENVVENO MEDICAL CORPORATION kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -100,00 % bei einem Aktienkurs von 9,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENVVENO MEDICAL CORPORATION finden Sie auf Wallstreet Online.